By: Quincy Attobrah From: oncnursingnews.com Datopotamab deruxtecan (Datroway) demonstrated improved progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in patients with previously untreated, advanced triple-negative breast cancer (TNBC) who were not eligible for immunotherapy, according to results from the phase 3 TROPION-Breast02 trial. The findings, published in Annals of Oncology, address a significant unmet need in TNBC, …
Palbociclib improves progression-free survival in HER2 positive breast cancer
Source: PrECOG, LLC From: news-medical.net PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England Journal of Medicine (NEJM). The study evaluated whether adding palbociclib to anti-HER2 and endocrine therapy, following induction chemotherapy, could delay disease progression in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) metastatic …
New discovery reveals crucial link between cholesterol and breast cancer progression
By: Natalia Krawczynska From: news-medical.net Cancer Center at Illinois (CCIL) Program Leader Erik Nelson’s lab made an important discovery about the relationship between cholesterol and breast cancer progression with crucial implications for breast cancer therapeutics. Breast cancer is the second leading cause of cancer-related death for American women, and more than 90% of breast cancer deaths are caused by metastatic spread of …
Tracking RNA levels reveals new clues in triple-negative breast cancer progression
By: Jen A. Miller, Cold Spring Harbor Laboratory From: medicalxpress.com When researchers look for potential cancer therapy targets, they typically go after protein-coding genes that participate in disease progression. Disrupt them and negate whatever role they play in cancer’s development or spread. Researchers at Cold Spring Harbor Laboratory (CSHL) have also been working on another kind of target. They’re studying …
HER2-Positive Breast Cancer Diet
From: healthline.com Foods such as sugar, saturated fats, and alcohol may promote the spread of HER2-positive breast cancer and should be avoided if you have this cancer. Some other foods may slow the cancer’s progress. Can diet help HER2-positive breast cancer? Your daily diet can affect your overall health. About 18% of all cancersTrusted Source may be related to diet, …
Innovative ctDNA model could improve cancer progression monitoring
Source: Elsevier From: news-medical.net In metastatic cancer surveillance, monitoring the actual concentrations of circulating tumor DNA (ctDNA) may be critical. Researchers showed that absolute ctDNA concentration thresholds can be defined to rule out or predict impending cancer progression. They introduce a dual threshold model in a novel study in The Journal of Molecular Diagnostics, published by Elsevier, that may improve …
New insights in breast cancer progression and drug resistance
Source: University of Liverpool From: eurekalert.org A significant breakthrough in breast cancer research has uncovered a key mechanism driving cancer invasion and drug resistance. A University of Liverpool study reveals how two critical molecules present in ‘HER2-positive’ breast cancer – one of the most aggressive forms – influence breast cancer survival and its spread. These proteins, HER2 and αVβ6 integrin, …
Powerful new therapy doubles progression-free survival in advanced breast cancer
From: cr.ac.uk A powerful three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new research has shown. The INAVO120 study, led by Professor Nicholas Turner of The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, demonstrates the potential of the …
Combination yields ‘promising PFS outcomes’ in certain patients with breast cancer
By: Matthew Shinkle From: healio.com Key takeaways: Two-thirds of patients experienced no disease progression 6 months after the start of treatment. Results showed increased durability among a subset of patients with HER2-positive disease. SAN ANTONIO — The combination of zanidatamab, palbociclib and fulvestrant yielded promising PFS results among adults with HER2-positive/hormone receptor-positive metastatic breast cancer, findings from a phase 2A …
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
By: Jordyn SavaKEYNOTE-522 From: targetedonc.com The addition of neoadjuvant pembrolizumab (Keytruda) to chemotherapy, followed by adjuvant pembrolizumab reduced the risk for recurrence, progression, complications, or death vs neoadjuvant chemotherapy alone in the KEYNOTE-522 study (NCT03036488) evaluating the combination in high-risk triple-negative breast cancer (TNBC).1 According to updated findings presented at the European Society for Medical Oncology (ESMO) 2023 Annual Congress, …
- Page 1 of 2
- 1
- 2